Antibiotic-Induced Release of Bacterial Cell Wall Components in the Pathogenesis of Sepsis and Septic Shock: A Review

Journal of Chemotherapy

Volumn 10, Issue 6, 1998, Pages 427-448

  Periti, P ^a,b   Mazzei, T ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b NONE   (Italy)

Author keywords

Antimicrobial chemotherapy; Chemoresistance; Endotoxins; Pharmacodynamics; Pharmacokinetics; Sepsis; Septic shock

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL TOXIN; ENDOTOXIN; LACTAM;

ANTIBIOTIC RESISTANCE; CELL WALL; HUMAN; MICROBIOLOGY; PATIENT SELECTION; PHYSIOLOGY; REVIEW; SECRETION; SEPSIS; SEPTIC SHOCK;

ANTI-BACTERIAL AGENTS; BACTERIAL TOXINS; CELL WALL; DRUG RESISTANCE, MICROBIAL; ENDOTOXINS; HUMANS; LACTAMS; PATIENT SELECTION; SEPSIS; SHOCK, SEPTIC;

EID: 0032245519     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1998.10.6.427     Document Type: Review

References (126)

1. Kirikae T, Nakano M, Morrison DC. Antibiotic-induced endotoxin release from bacteria and its clinical significance - Review. Microbiol Immunol 1997; 41 (4): 285-294.
2. Vincent J-L. New therapies in sepsis. Chest 1997; 112: 330S-338S.
3. Holzheimer RG. The significance of endotoxin release in experimental and clinical sepsis in surgical patients - Evidence for antibiotic-induced endotoxin release? Infection 1998; 26 (2): 77-84.
4. Periti P, Mazzei T, De Gaudio AR, Tonelli F. Attuali orientamenti nella scelta e modalità di somministrazione degli agenti antimicrobici per una razionale chemioterapia della sepsi grave. Farm Ter 1998; XV (1/2): 3-23.
5. Finch RG. Design of clinical trials in sepsis: problems and pitfalls. J Antimicrob Chemother 1998; 41 (Suppl A): 95-102.
6. Nyström P-O. The systemic inflammatory response syndrome: definitions and aetiology. J Antimicrob Chemother 1998; 41 (Suppl A): 1-7.
7. Singer M. Management of multiple organ failure: guidelines but no hard-and-fast rules. J Antimicrob Chemother 1998; 41 (Suppl A): 103-112.
8. Hurley JC, Louis WJ, Tosolini FA, Carlin JB. Antibiotic-induced release of endotoxin in chronically bacteriuric patients. Antimicrob Agents Chemother 1991; 35 (11): 2388-2394.
9. Jackson JJ, Kroop H. β-lactam antibiotic-induced release of free endotoxin: in vitro comparison of penicilling-binding protein (PBP) 2-specific imipenem and PBP 3-specific ceftazidime. J Infect Dis 1992; 165: 1033-1041.
10. Hurley JC. Antibiotic-induced release of endotoxin: a reappraisal. Clin Infect Dis 1992; 15: 840-854.
11. Bucklin SE, Fujihara Y, Leeson MC. Morrison DC. Differential antibiotic-induced release of endotoxin from Gramnegative bacteria. Eur J Clin Microbiol Infect Dis 1994; 13 (Suppl 1): 43-51.
12. Nitsche D, Schulze C, Oesser S, Dalhoff A, Sack M. Impact of different classes of antimicrobial agents on plasma endotoxin activity. Arch Surg 1996; 131: 192-199.
13. Horn DL, Opal SM, Lomastro E. Antibiotics, cytokines, and endotoxin: a complex and evolving relationship in Gram-negative sepsis. Scand J Infect Dis 1996; Suppl 101: 9-13
14. Stuertz K, Schmidt H, Eiffert H, Schwartz P, Mäder M, Nau R. Differential release of lipoteichoic and teichoic acids from Streptococcus penumoniae as a result of exposure to β-lactam antibiotics, rifamycins, trovafloxacin, quinupristin-dalfopristin. Antimicrob Agents Chemother 1998; 42 (2): 277-281.
15. Mattsson EL, Verhage L, Rollof K, Fleer A, Verhoef J, Van Dijk H. Peptidoglycan and teichoic acid from Staphylococcus epidermidis stimulate human monocytes to release tumour necrosis factor α, interleukin-1β and interleukin-6. FEMS Immunol Med Microbiol 1993; 7: 281-288.
16. Timmerman CP, Mattson E, Martinez-Martinez L, et al. Induction of tumor necrosis factor from human monocytes by staphylococci and staphylococcal peptidoglycans. Infect Immun 1993; 61: 4167-4172.
17. Frieling JTM, Mulder JA, Hendriks T, Curfs JHAJ, Van der Linden CJ, Sauerwein RW. Differential induction of pro-and anti-inflammatory cytokines in whole blood by bacteria: effects of antibiotic treatment. Antimicrob Agents Chemother 1997; 41 (7): 1439-1443.
18. Reilly J, Compagnon A, Tuornier P, Bastin R, DuBuit H. Les accidents du traitment des fievres typhoides par la chloromycetine. Ann Med (Paris) 1950; 51: 597-629.
19. Shenep JL, Flynn PM, Barrett FF, Stidham GL, Westenkirchner DF. Serial quantitation of endotoxemia and bacteremia during therapy for Gram-negative bacterial sepsis - Concise communications. J Infect Dis 1988; 157 (3): 565-568.
20. Gotto H, Nakamura S. Liberation of endotoxin from Escherichia coli by addition of antibiotics. Jpn J Exp Med 1980; 50: 35-43.
21. Cohen J, McConnell JS. Release of endotoxin form bacteria exposed to ciprofloxacin and its prevention with polymyxin B. Eur J Clin Microbiol 1986; 5: 13-17.
22. Shenep JL, Barton RP, Mogan KA. Role or antibiotic class in the rate of liberation of endotoxin during therapy for experimental Gram-negative bacterial sepsis. J Infect Dis 1985; 151: 1012-1018.
23. Rokke O, Revhaug A, Osterud B, Giercksky KE. Increased plasma levels of endotoxin and corresponding changes in circulatory performance in a porcine sepsis model: the effect of antibiotic administration. Prog Clin Biol Res 1988; 272: 262-274.
24. Shenep JL, Mogan KA. Kinetics of endotoxin release during antibiotic therapy for experimental Gram-negative bacterial sepsis. J Infect Dis 1984; 150: 380-388.
25. Cohen J, McConnell JS. Antibiotic-induced endotoxin release. Lancet 1985; 2: 1069-1070.
26. Gemmel C, Lorian V. Effects of low concentrations of antibiotics on bacterial ultrastructure, virulence, and susceptibility to immunodefenses: clinical significance. In: "Antibiotics in Laboratory Medicine" (Lorian V. Ed), Fourth Edition. Williams and Wilkins, Baltimore 1996; 397-452.
27. Neu HC. Relation of structural properties of beta-lactam antibiotics to antibacterial activity. Am J Med 1985; 79 (Suppl 2A): 2-13.
28. Dofferhoff ASM, Buys J. The influence of antibiotic-induced filament formation on the release of endotoxin from Gram-negative bacteria. J Endotoxin Res 1996; 3: 187-194.
29. Jackson JJ, Kropp H. Differences in mode of action of β-lactum antibiotics influence morphorogy, LPS release and in vivo antibiotic efficacy. J Endotoxin Res 1996; 3: 201-218.
30. Nakano M, Kirikae T. Biological characterization of Pseudomonas aeruginosa endotoxin released by antibiotic treatment in vitro. J Endotoxin Res 1996; 3: 195-200.
31. Eng RHK, Hsieh A, Smith SM. Antibiotic killing of bacteria: comparison of bacteria on surfaces and in liquid, growing and nongrowing. Chemotherapy 1995; 41: 113-120.
32. Cozens RM, Tuomanen E, Tosch W, Zak O, Suter J, Tomasz A. Evaluation of bactericidal activity of β-lactam antibiotics on slowly growing bacteria cultured in the chemostat. Antimicrob Agents Chemother 1986; 29: 797-802.
33. Pucci MJ, Boice-Sowek J, Kessler RE, Dougherty TJ. Comparison of cefepime, cefpirome, and cefaclidine binding affinities for penicillin-binding proteins in Escherichia coli K-12 and Pseudomonas aeruginosa SC8329. Antimicrob Agents Chemother 1991; 35 (11): 2312-2317.
34. Hanberger H, Nilsson LE, Kihlström E, Maller R. Postantibiotic effect of β-lactam antibiotics on Escherichia coli evaluated by bioluminescence assay of bacterial ATP. Antimicrob Agents Chemother 1990; 34 (1): 102-106.
35. Lorian V, Atkinson B. Abnormal forms of bacteria produced by antibiotics. Am J Clin Pathol 1975; 64: 678-688.
36. Georgopapadakou NH, Liu FY. Penicillin binding proteins in bacteria. Antimicrob Agents Chemother 1980; 18: 148-153.
37. Lorian V. Phagocytosis of staphylococci after exposure to antibiotics. J Antimicrob Chemother 1985; 16: 129-133.
38. P. Periti, T. Mazzei, E. Mini, A. Novelli, E.F. Reali (eds ): "Attualità delle Cefalosporine in Chemioterapia". E.R.S., Firenze, 1988: 3-207
39. Satta G, Cornaglia G, Mazzariol A, Golini G, Valisena S, Fontana R. Target for bacteriostatic and bactericidal activities of β-lactam antibiotics against Escherichia coli resides in different penicillin-binding proteins. Antimicrob Agents Chemother 1995; 39 (4): 812-818.
40. Gould IM, MacKenzie FM. The response of enterobacteriaceae to β-lactam antibitoics - 'round forms, filaments and the root of all evil'. J Antimicrob Chemother 1997; 40: 495-499
41. Chase HA, Fuller C, Reynolds PE. The role of penicillin-binding proteins in the action of cephalosporins against Escherichia coli and Salmonella typhimurium. Eur J Biochem 1981; 117: 301-310.
42. Williamson R, Gutmann L, Kitzis MD, Acar JF. An evaluation of the bacteriolytic and biochemical properties of ceftiolene (42980 RP). J Antimicrob Chemother 1984; 14: 581-593.
43. Gutmann L, Vincent S, Blllot-Klein D, Acar JF, Mréna E, Williamson R. Involvement of penicillin-binding 2 with other penicillin-binding proteins in lysis of Escherichia coli by some beta-lactam antibiotics alone and in synergistic lytic effect of amidinocillin (mecillinam). Antimicrob Agents Chemother 1986; 30: 906-912.
44. Satta G, Cornaglia G, Canepari P, Pompei R. Evaluation of bactericidal activity of cefotaxime and other beta-lactams by a novel method. Drugs 1988; 35 (Suppl 2): 35-40.
45. Satta G, Fontana R, Canepari P. The two-competing site (TCS) model for cell shape regulation in bacteria: the envelope as an integration point for the regulatory circuits of essential physiological events. Adv Microb Physiol 1994; 36: 181-245.
46. Fontana R, Valisena S, Cornaglia G. Comparative affinities for penicillin-binding proteins of multipolar ionic amphoteric cephalosporins in Gram-negative bacteria. J Chemother 1996; 8 (Suppl 2): 23-30.
47. Kahan FM, Kropp H, Sundelof IG, Birnbaum J. Thienamycin: development of imipenem-cilastin. J Antimicrob Chemother 1983; 12 (Suppl D): 1-35.
48. Soriano F. Optimal dosage of β-lactam antibiotics: time above the MIC and inoculum effect. J Antimicrob Chemother 1992; 30: 566-569.
49. Johnson CC, Livornese L, Gold MJ, Pitsakis PG, Taylor S, Levison ME. Activity of cefepime against ceftazidime-resistant Gram-negative bacilli using low and high inocula. J Antimicrob Chemother 1995; 35: 765-773.
50. Stevens DE, Yan S, Bryant AE. Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for tne inoculum effect. J Infect Dis 1993; 167: 1401-1405.
51. Sande MA, Mandel GL. Antimicrobial agents. General considerations. In: "Goodman and Gilman's The Pharmacological Basis of Therapeutics" (Gilman AG, Goodman LS, Gilman A, Eds), 6th edn. MacMillan, New York 1980: 1080-1105.
52. Ellner PD, Neu HC. The inhibitory quotient. J Am Med Ass 1981; 246: 1575-1578.
53. Soriano F, Ponte C, Santamaria M, Jimenez-Arriero M. Relevance of the inoculum effect of antibiotics in the outcome of experimental infections caused by Escherichia coli. J Antimicrob Chemother 1990; 25: 621-627.
54. Mackenzie FM, Gould IM. The postantibiotic effect. J Antimicrob Chemother 1993; 32: 519-537.
55. Hanberger H, Nilsson LE, Nilsson M, Maller R. Postantibiotic effect of beta-lactam antibiotics on Gram-negative bacteria in relation to morphology, initial killing and MIC. Eur J Clin Microb Infect Dis 1991; 10: 927-934.
56. MacKenzie FM, Gould IM, Chapman DG, Jason D. Comparison of methodologies used in assessing the postantibiotic effect. J Antimicrob Chemother 1994; 34: 223-230.
57. Gudmundsson S, Vogelman B, Craig WA. The in vivo postantibiotic effect of imipenem and other new antimicrobials. J Antimicrob Chemother 1986; 18 (Suppl E): 67-73.
58. Vogelman B, Gudmunsson S, Turnidge I, Leggett I, Craig WA. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis 1988; 157: 287-289.
59. Hurley JC. Reappraisal of the role of endotoxin in the sepsis syndrome. Lancet 1993; 341: 1133-1135.
60. Periti P, Mazzei T. Attualità farmacocinetiche, farmacodinamiche e posologiche della claritromicina. Farm Ter 1998; XV (1/2): 34-50.
61. Wiedemann B, Grimm H. Susceptibility to antibiotics: species incidence and trends. In: "Antibiotics in Laboratory Medicine" (Lorian V, Ed), Fourth Edition. Williams and Wilkins, Baltimore 1996: 900-1168.
62. Stratton CW. Mechanisms of action for antimicrobial agents: general principles and mechanisms for selected classes of antibiotics. In: "Antibiotics in Laboratory Medicine" (Lorian V, Ed), Fourth Edition. Williams and Wilkins, Baltimore 1996: 579-603.
63. Smith II. Microbial surfaces in relation to pathogenicity. Bacteriol Rev 1977; 4: 475-500.
64. Brown MRW, Collier PJ, Gilbert P. Influence of growth rate on susceptibility to antimicrobial agents: modification of the cell envelope and batch and continuous culture studies. Antimicrob Agents Chemother 1990; 34: 1623-1628.
65. Periti P. Preclinical and clinical evaluation of once-daily aminoglycoside chemotherapy. J Chemother 1995; 7 (4): 311-337.
66. Dofferhoff ASM, Esselink MT, de Vries-Hospers HG, et al. The release of endotoxin from antibiotic-treated Escherichia coli and production of tumour necrosis factor by human monocytes. J Antimicrob Chemother 1993; 31: 373-384.
67. Bingen E, Goury V, Bennani H, Lambert-Zechovsky N, Aujard Y, Darbord JC. Bactericidal activity of β-lactamas and amikacin against Haemophilus influenzae: effect on endotoxin release. J Antimicrob Chemother 1992; 30: 165-172.
68. Prins JM, Van Deventer SJH, Kuijper EJ, Speelman P. Clinical relevance of antibiotic-induced endotoxin release. Antimicrob Agents Chemother 1994; 38 (6): 1211-1218.
69. Prins JM, Van Agtmael MA, Kuijper EJ, Van Deventer SJF, Speelman P. Antibiotic-induced endotoxin release in patients with Gram-negative urosepsis: a double-blind study comparing imipenem and ceftazidime. J Infect Dis 1995; 172: 886-891.
70. Nguyen-Distèche M, Fraipont C, Buddelmeijer N, Nanninga N. The structure and function of Escherichia coli penicilling-binding protein 3. CMLS, Cell Mol Life Sci 1998; 54: 309-316.
71. Mock CN, Jurkovich GJ, Dries DJ, Maier RV. Clinical significance of antibiotic endotoxin-releasing properties in trauma patients. Arch Surg 1995; 130: 1234-1241.
72. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regiments for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22: 89-96.
73. Schentag J. Pharmacokinetic issues and implications. 2nd European Congress of Chemotherapy and 7th Biennal Conference on Antiinfective Agents and Chemotherapy, May 10-13, 1998 Hamburg, Final Programme. Futuramed, Germany 1998: 94.
74. Kirikae T, Kirikae F, Saito S, et al. Biological characterization of endotoxins released from antibiotic-treated Pseudomonas aeruginosa and Escherichia coli. Antimicrob Agents Chemother 1998; 42 (5): 1015-1021.
75. Van Langeveld P, Kwappenberg KM, Groeneveld PHP, Mattie H, Van Dissel JT. Antibiotic-induced lipopolysaccharide (LPS) release from Salmonella typhi: delay between killing by ceftazidime and imipenem and release of LPS. Antimicrob Agents Chemother 1998; 42 (4): 739-743.
76. Trautmann M, Zick R, Rukavina T, Cross AS, Marre R. Antibiotic-induced release of endotoxin: in-vitro comparison of meropenem and other antibiotics. J Antimicrob Chemother 1998; 41: 163-169.
77. Tuomanen E, Gilbert K, Tomasz A. Modulation of bacteriolysis by cooperative effects of penicillin-binding proteins 1a and 3 in Escherichia coli. Antimicrob Agents Chemother 1986; 30: 659-663.
78. Dofferhoff AS, Esselink MT, De Vries-Hospers HG, et al. The release of endotoxin from antibiotic-treated Escherichia coli and the production of tumour necrosis factor by human monocytes. J Antimicrob Chemother 1991; 31: 373-384.
79. Mattie H, Razab Sekh BA, Van Ogtrop ML, Van Strijen E. Comparison of the antibacterial effects of cefepime and ceftazidime against Escherichia coli in vitro and in vivo. Antimicrob Agents Chemother 1992; 36 (11): 2439-2443.
80. Pechère JC, Wilson W, Neu H. Laboratory assessment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins. J Antimicrob Chemother 1995; 36: 757-771.
81. Then RL, Anghern P. Ways to overcome cephalosporinase mediated β-lactam resistance in Enterobacter cloacae. Chemioterapia 1985; 4: 83-93.
82. Pryka RD, Haif GM. Meropenem: a new carbapenem antimicrobial. Ann Pharmacother 1994; 28: 1045-1054.
83. Evans ME, Pollack M. Effect of antibiotic class and concentration on the release of lipopolysaccharide from Escherichia coli. J Infect Dis 1993; 167: 1336-1343.
84. Van Der Berg C, De Neeling AJ, Schot CS, Hustinx WNM, Wemer J, De Wildt DJ. Delayed antibiotic-induced lysis of Escherichia coli in vitro is correlated with enhancement of LPS release. Scand J Infect Dis 1992; 24: 619-627.
85. Horii T, Kobayashi M, Sato K, Ichiyana S, Ohta M. An in-vitro study of carbapenem-induced morphological changes and endotoxin release in clinical isolates of Gram-negative bacilli. J Antimicrob Chemother 1998; 41: 435-442.
86. Bax RP. Antibiotic resistance: a view from the pharmaceutical industry. Clin Infect Dis 1997; 24 (Suppl 1): S151-S153.
87. Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factros associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42 (3): 521-527.
88. Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Clin Pharmacokinet 1995; 28: 143-160.
89. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996; 15: 255-259.
90. Madaras-Kelly KJ, Ostergaard BE, Hovde LB, Rotschafer JC. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob Agents Chemother 1996; 40: 627-632.
91. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073-1081.
92. Goss TF, Forrest A, Nix DE, et al. Mathematical examination of dual individual principles. II. The rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime. Ann Pharmacother 1994; 28: 863-868.
93. Schentag JJ, Nix DE, Forrest A, Adelman MH. AUIC-the universal parameter within the constraint of a reasonable dosing interval. Ann Pharmacother 1996; 30: 1029-1031.
94. Vogelman B, Craig WA. Kinetics of antibacterial activity. J Pediatr 1986; 108: 835-840.
95. Craig WA, Redington J, Ebert SC. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 1991; 27 (Suppl C): 29-40.
96. Craig WA, Gudmundsson S. Postantibiotic effect. In: "Antibiotics in Laboratory Medicine" (Lorian V, Ed), Fourth Edition. Williams and Wilkins, Baltimore 1996: 296-330.
97. Ter Braak EW, De Vries PJ, Bouter SG, et al. Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: a comparative trial with netilmicin plus ceftriaxone. Am J Med 1990; 89: 58-66.
98. Nicolau DP, Freeman CD, Belliveau PB, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995; 39: 650-655.
99. McGowan AP, Bowker KE. Pharmacodynamics of antimicrobial agents and rationale for their dosing. J Chemother 1997; 9: 64-73.
100. Craig WA, Ebert SC. Continuous infusion of β-lactam antibiotics - Minireview Antimicrob Agents Chemother 1992; 36 (12): 2577-2583.
101. Mouton JW, Den Hollander JG. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1994; 38: 931-936.
102. Mouton JW, Vinks AATMM. Is continuous infusion of β-lactam antibiotics worthwhile? - efficacy and pharmacokinetic conciserations - Review. J Antimicrob Chemother 1996; 38: 5-15.
103. Mouton JW, Vinks AATMM, Punt NC. Pharmacokinetic-pharmacodynamic modeling of activity of ceflazidime during continuous and intermittent infusion. Antimicrob Agents Chemother 1997; 41 (4): 733-738.
104. Yourassowsky E, Van der Linden MP, Lismont MJ, Crokaert F. Turbidimetric and microscopic analysis of Bacteroides fragilis exposed to tazobactam and piperacillin alone and in combination. Chemotherapy 1990; 36: 215-221.
105. Moosdeen F, Williams JD, Yamabe S. Antibacterial charactertistics of YTR 830, a sulfone beta-lactamase inhibitor, compared with those of clavulanic acid and sulbactam. Antimicrob Agents Chemother 1988; 32, 6: 925-927.
106. Qadri SM, Ueno Y, Cunha BA. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors. Chemotherapy 1996; 42, 5: 334-342.
107. Bohme A, Shah PM, Stille W, Hoelzer D. Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study. Eur J Med Res 1998; 3, 7: 324-330.
108. Den-Hollander JG, Mouton JW, Verbrugh HA. Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics. Antimicrob Agents Chemother 1998; 42 (4): 744-748.
109. Davis BD. The lethal action of aminoglycosides. J Antimicrob Chemother 1988; 22: 1-3.
110. Kadurugamuwa JL, Beveridge TJ. Natural release of virulence factors in membrane vesicles by Pseudomonas aeruginosa and the effect of aminoglycoside antibiotics on their release. J Antimicrob Chemother 1997; 40: 615-621.
111. McConnell JS, Cohen J. Release of endotoxin from Escherichia coli by quinolones. J Antimicrob Chemother 1986; 18: 765-773.
112. Simon DM, Koenig G, Trenholme GM. Differences in release of tumor necrosis factor from THP-1 cells stimulated by filtrates of antibiotic-killed Escherichia coli. J Infect Dis 1991; 164: 800-802.
113. Nitsche D, Schulze C, Eosser S, Dalhoff A, Sack M. The effects of different types of antimicrobial agents on plasma endotioxin activity in Gram-negative bacterial infection. In: "Ciprofloxacin i.v., defining its role in serious infections" (Garrard G, Ed). Springer, Berlin Heidelberg New York 1994: 21-36.
114. Dalhoff A. Interaction of quinolones with host-parasite relationship. In: "Quinolone Antibacterial" (Kuhlmann J, Dalhoff A, Eds). Springer, Berlin 1998; Chapter 8: 233-253.
115. Zabel P, Schade FU. Pentoxifylline and tumour necrosis factor-induced lung injury. Eur Respir J 1994; 7: 1389-1391.
116. Curfs JHAJ, Meis JFGM, Hoogkamp-Korstanje JAA. A primer on cytokines: sources, receptors, effects, and inducers. Clin Microbiol Review 1997; 10 (4): 742-780.
117. Gardlund B, Sjölin J, Nilsson A, Roll M, Wickerts CJ, Wretlind B. Plasma levels of cytokines in primary septic shock in humans: correlation with disease severity. J Infect Dis 1995; 172: 296-301.
118. Kusser WC, Ishiguro EF. Effects of aminoglycosides and spectinomycin on the synthesis and release fo lipopolysaccharide by Escherichia coli. Antimicrob Agents Chemother 1988; 32 (8): 1247-1250.
119. Artenstein AW, Cross AS. Inhibition of endotoxin reactivity by aminoglycosides. J Antimicrob Chemother 1989; 24 (5): 826-828
120. Focà A, Matera G, Iannello D, Berlinghieri MC, Liberto MC. Aminoglycosides modify the in vitro metachromatic reaction and murine generalized Schwartzman phenomenon induced by Salmonella minnesota R595 lipopolysaccharide. Antimicrob Agents Chemother 1991; 35: 2161-2164.
121. Focà A, Mater G, Berlinghieri MC, Liberto MC, De Sarro GB. Teicoplanin reduces in-vitro reactivity and murine lethality of Salmonella minnesota R595 lipopolysaccharide. J Antimicrob Chemother 1992; 29: 443-446.
122. Focà A, Matera G, Berlinghieri MC. Inhibition of endotoxin-induced interleukin 8 release by teicoplanin in human whole blood. Eur J Clin Microbiol Infect Dis 1993; 12: 940-944.
123. Siedlar M, Szczepanik A, Wieckiewicz J, Pituch-Noworolska A, Zembala M. Vancomycin down-regulates lipopolysaccharide-induced tumour necrosis factor alpha (TNFα) production and TNFα-mRNA accumulation in human blood monocytes - Short communication. Immunopharmacology 1997; 35: 265-271.
124. Hack CE, Hart M, Strack van Schijndel RJM, et al. Interleukin-8 in sepsis: relation to shock and inflammatory mediators. Infect Immun 1992; 60: 2835-2842.
125. Eliopoulos GM, Moellering R. Antimicrobial combinations. In: "Antibiotics in Laboratory Medicine" (Lorian V, Ed), Fourth Edition. Williams and Wilkins, Baltimore 1996: 330-396.
126. Den-Hollander JG, Horrevorts AM, Van Goor MPJ, Verbrugh HA, Mouton JW. Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1997; 41: 95-100.